Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Mazorra, Zaima, Lavastida, Anabel, Concha-Benavente, Fernando, Valdés, Anet, Srivastava, Raghvendra M., García-Bates, Tatiana M., Hechavarría, Esperanza, González, Zuyen, González, Amnely, Lugiollo, Martha, Cuevas, Iván, Frómeta, Carlos, Mestre, Braulio F., Barroso, Maria C., Crombet, Tania, Ferris, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://ncbi.nlm.nih.gov/pubmed/28674498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados